MULTIPLE MYELOMA HEMATOLOGY AND TREATMENT IN ANCHORAGE, AK

OFFERING SUPPORT FOR MULTIPLE MYELOMA

At Alaska Oncology and Hematology, LLC in Anchorage, AK, we are committed to giving patients with multiple myeloma individualized, evidence-based therapy. Our multidisciplinary professional team works together to create personalized treatment programs that are suited to the particular requirements of every patient.

A complicated and uncommon kind of blood cancer that targets bone marrow-resident plasma cells, or white blood cells, is called multiple myeloma. Multiple myeloma is a difficult disease to diagnose, treat, and manage. Patients suffering from this illness can receive comprehensive care and support from Alaska Oncology and Hematology, LLC. We’ll be happy to answer any questions you might have!

OUR MULTIPLE MYELOMA TREATMENT OPTIONS

Chemotherapy, immunotherapy, targeted therapy, stem cell transplantation, radiation therapy, bispecific monoclonal antibodies, or a combination of these interventions are possible treatments for multiple myeloma. Our experts regularly participate in clinical studies to provide our patients with access to innovative therapeutics and stay up to date on the most recent developments in multiple myeloma research.

We recognize that people with multiple myeloma require supportive care in addition to medicinal treatments. We provide a variety of programs to address nutritional needs, pain management, bone health, and mental wellness.

TREATMENT OPTIONS

1. Chemotherapy: Drugs used to treat multiple myeloma frequently include pomalidomide, lenalidomide, and bortezomib. They function by identifying and eliminating cancer cells that divide quickly.

2. Immunomodulatory medications: medications such as pomalidomide, lenalidomide, and thalidomide improve the immune system's defense against myeloma cells and aid in the disease's management.

3. Proteasome Inhibitors: Proteasomes are cellular structures that break down proteins. Proteasome inhibitors, such bortezomib, carfilzomib, and ixazomib, hinder their activity. Proteasome inhibitors work by interfering with this mechanism, which causes myeloma cells to accumulate toxic proteins that eventually kill them.


4. Monoclonal Antibodies: Myeloma cell surface proteins are targeted by monoclonal antibodies, such as daratumumab and elotuzumab, which help destroy the cancer cells. Bispecific monoclonal antibodies are a relatively new class of monoclonal antibodies that have the ability to attach to two targets at once, increasing their potency.

5. Corticosteroids: Used in conjunction with other therapies, corticosteroids, such as dexamethasone or prednisone, reduce inflammation, suppress the immune system, and aid in the regulation of myeloma cell proliferation.

6. Stem Cell Transplantation: To restore healthy bone marrow function, suitable individuals may be considered for autologous (using the patient's own stem cells) or allogeneic (using stem cells from a donor) stem cell transplantation.


7. Chimeric Antigen Receptor (CAR) T-cell Therapy: This cutting-edge immunotherapy alters a patient's own T-cells to identify and eliminate cancerous cells. Treatment for some forms of myeloma using CART-cell therapy has demonstrated encouraging outcomes.

8. One type of immunotherapy medications that has showed promise in the treatment of myeloma is bispecific monoclonal antibodies (bsAbs). These antibodies are designed to attach to two distinct targets at the same time, usually an immune cell receptor and a surface marker for cancer cells. Because of their dual binding method, bsAbs can reroute immune cells so they can target and kill cancer cells selectively.

Share by: